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In this paper, a chemometrical approach is applied for the
development of a reversed-phase high-performance liquid
chromatography method for the simultaneous determination of
mycophenolate mofetil and its degradation product mycophenolic
acid in dosage form. The fractional factorial design is used in
screening experiments for selecting the variables that significantly
influence the chromatographic procedure. The investigated
variables are column type, temperature of the column, and
composition of the mobile phase (with respect to pH and the
percentage of organic modifier). Investigation is performed using
two columns, XTerra (RP 18, 150 mm × 3.9 mm) and Chromolith
(RP-18e, 100 mm × 4.6 mm). Because the column type shows no
influence on separation process, the Chromolith column is further
used due to its ability to achieve a high-speed separation without
loss of column efficiency. Total analysis time is reduced from 8.34
min on XTerra to 1.27 min on Chromolith. The columns’ efficiency,
analysis cost, and peak symmetries are briefly compared. For both
substances, only two variables are found significant: percentage of
acetonitrile and pH of the water phase. Afterward, the main
variables are optimized using response surface methodology for
visualization and easier identification of optimal conditions. The
optimal conditions are obtained with mobile phase composition of
acetonitrile–15mM phosphate buffer (pH adjusted to 4.0 with 85%
orthophosphoric acid) (35:65, v/v) at the flow rate of 5 mL/min.
The temperature of the column is adjusted to 25°C and detection
is performed at 254 nm.
Introduction
Mycophenolate mofetil (MMF, Figure 1A) is an immuno-
suppressive drug which is most frequently used in combination
with prednisone after solid organ transplantation. Also, it is
often used for the treatment of renal disease due to systemic
lupus erythematosus and may be useful in vasculitis and
Wegener granulomatosis. On the other hand, it is occasionally
administrated to treat rheumatoid arthritis, as there are few
controlled data regarding its efficacy in this area.
MMF is a pro drug which is rapidly absorbed and hydrolyzed
to mycophenolic acid (MPA, Figure 1B), the active metabolite
(1). According to the manufacturer’s specification, the hydrol-
ysis process can also occur in dosage form during the storage
of Cellcept capsules and as the level of MPA increases. Degra-
dation products are considered as impurities which might lead
to problems associated with toxicity, bioavailability, or dif-
ferent pharmaceutical products’ performance. As the level of
degradation of MMF directly influences its bioavailability, MPA
is always investigated as an impurity in dosage form. At the
same time, according to International Conference on Harmo-
nization (ICH) guidelines on impurities in new drug products,
identification and quantitation is necessary for all impurities
above 0.1% level (2,3). The control specification for MPA in
capsule formulation is up to a maximum 1%.
Considering this, a new isocratic, reversed-phase high-per-
formance liquid chromatography (RP-HPLC) method was
developed and validated for the simultaneous determination
of MMF and its degradation product in dosage form. This is
the first study in which quantitative analysis was performed
for the simultaneous determination of MMF and MPA. In the
literature is found only methods for the determination of
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MMF or MPA in biological materials (4–11). Most of them use
ion pair reagents (5,8,10,11), and require a change of flow
rate (6) or even gradient elution (7). The liquid chromatog-
raphy–mass spectrometry (LC–MS) method for the quantita-
tion of MPA has also been established (12). As few laboratories
are in a position to perform LC–MS, a new sensitive, precise,
and rapid RP-HPLC–UV method for the determination of
MMF and MPA in dosage forms in routine analysis is welcome
in this area. There are no reported papers from dosage form,
either.
Many studies show the performance of monolith columns
(13–18) and compare these columns with conventional
reversed-phase columns (19–23), but there are no papers about
the performance of monolithic columns against the XTerra
column. In order to decide whether to use the Chromolith or




HPLC analysis was performed with an Agilent Technologies
(Palo Alto, CA) HP 1100 chromatograph equipped with HP
1100 binary pump, HP 1100 UV-visible detector, and Rheo-
dine 20-µL loop injector. Compounds were separated on an
XTerra RP 18, 150 mm × 3.9 mm, 5 µm particle size column
(Waters, Milford, MA), as well as on a Chromolith RP-18e, 100
mm × 4.6 mm, macropore size 2 µm, mesopore size 13 nm
(Merck, Darmstadt, Germany) column. 
Water for chromatography was obtained from a Millipore
(Billerica, MA) System Simplicity 185 purification system.
Before use, the mobile phase and the solutions to be injected
were degassed and vacuum filtered through 0.45 µm nylon
membranes (Alltech Associates, Lokeren, Belgium). 
Data was acquired with ChemStation software from HP. For
linear regression and statistical analysis, Microsoft Excel ver-
sion software was used. The polynomial equations and response
surface plots were achieved from Statistica 5 software.
Drugs and materials
MMF and MPA standards were purchased from Sigma
(Taufkirchen, Germany). Commercially available Cellcept 
capsules (one capsule contains 250 mg of MMF) were pro-
duced by Roche (Nutley, NJ).
HPLC-grade acetonitrile was obtained from Lab Scan
(Dublin, Ireland), potassium dihydrogen phosphate from
Merck, 85% orthophosphoric acid from Carlo Erba (Milan,
Italy), and phenacetin was a U.S. Pharmacopeia reference 
substance.
Chromatographic conditions
The chosen mobile phase for the separation of MMF and its
degradation product MPA on the XTerra column consisted of
acetonitrile–15mM KH2PO4 buffer, in which pH was adjusted to
4.0 with 85% orthophosphoric acid (35:65, v/v). For the Mono-
lith column, it consisted of acetonitrile–15mM KH2PO4 buffer,
in which pH was adjusted to 4.2 with 85% orthophosphoric
acid (35:65, v/v). Flow rate was 1 mL/min for XTerra and 5
mL/min for Chromolith, and detection was performed at 254
nm on both columns.
Standard and test solutions
A stock solution of MMF was prepared at a concentration of
1 mg/mL in 50:50 (v/v) acetonitrile–water as a solvent. A stock
solution of MPA was prepared in the same solvent as MMF at a
concentration of 0.1 mg/mL. A 0.1 mg/mL stock solution of
phenacetin as internal standard was also prepared in 50:50
(v/v) acetonitrile–water.
For construction of calibration curve, standard solutions
were prepared at concentrations of 0.05; 0.1; 0.2; 0.3; 0.4; 0.5
mg/mL for MMF and at concentrations of 0.5; 1; 2; 3; 4; 5
µg/mL for MPA.
Test solutions were prepared from Cellcept capsules. Capsule
powder containing 25 mg of MMF was transferred to a 25-mL
volumetric flask and dissolved in approximately 20 mL of 50:50
(v/v) acetonitrile–water by use of an ultrasonic bath for 15
min. The solution was then diluted to volume with the same
solvent and filtered. The concentration of MMF was 1 mg/mL.
This solution was used to attain a test solution in a final con-
centration of 0.2 mg/mL for MMF.
Standard solutions of MMF and MPA used for validation
process as well as test solutions were prepared in mobile phase,
with the addition of internal standard, which was added to
obtain the final concentration of 10 µg/mL.
Experimental design and methodology
In the first step of the investigation, experimental design was
used to determine variables which have statistically impor-
tant influence on the chromatographic behavior of the inves-
tigated compounds. However, if the number of variables to be
optimized becomes large, this will increase the number of
experiments (24). When applying experimental design method-
ologies, it is advisable to keep the number of variables as low as
possible in order to avoid very complex response models and
large variability (25). Considering this, in the case of detailed
modeling it is often desirable at a first stage to reduce the
number of factors via screening design to a smaller number of
main factors that are to be studied in detail (employing opti-
mization designs), for which both squared and interaction
terms in the model are of interest (26). Applying fractional
factorial design, the number of experiments can be kept low,
based on the assumption that interaction effects between three
or more variables are small compared to main effects and two-
variable interaction effects. Thus, it is possible to select a frac-
tion of the full factorial design and omit several combinations
of variables from the experimental plan (27). The number of
experiments in fractional factorial design is given as 2k–p + C,
where k is the number of variables, C the number of replicates,
and p a whole number that indicates how fractionated the
experimental design will be. When p is zero, the experimental
design is full (24). The repetition of experiments provided a pre-
cise estimate of an experimental error. 
The statistical model for analyzing the screening design
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Yx1x2x3x4 = β0 + β1x1i + β2x2i + β3x3i + β4 x4i + r1i Eq. 1
where Y is the response variable, β0 is the general mean, β1, β2,β3 and β4 are the estimated factor effects, r1i is the residual
error, and x1, x2, x3, and x4 are the levels of each factor. In the
screening design, only two levels were used so that the factors
were considered as discrete variables and no continuous second
order response model could be estimated. The effect of each
factor was tested using a Student test with a corresponding
p-value. The factors whose p-values were less than 0.05 were
considered as “statistically significant”. A graphical display of
the ordered standardized effect (the absolute value of the esti-
mated effect divided by its standard error estimate) of each
factor was given in a Pareto chart. A factor was considered as
“statistically significant” if its standardized effect exceeded a
threshold. A line in the Pareto chart indicated the threshold for
a test at level 0.05 (28,29).
In the second step of the optimization, response surface
methodology (RSM) was applied. RSM presents a collection of
mathematical and statistical techniques for analyzing the effect
of several independent variables on dependent variables and
provides its graphical representation. The effect of two variables
can be represented as a surface in three-dimensional space
and the influence of two variables on the response can be
clearly seen in the investigated region. Furthermore, the
response surface methodology enables the prediction of the
behavior of the response between and slightly outside the
investigated area, as well as visualization and rapid selection of
optimal conditions (30).
When investigating the influence of two variables, the
response surface might be described by some mathematical
function, f, that relates the response, Y, to the levels of factors
x1 and x2:
y = f (x1, x2) Eq. 2 (28).
Results and Discussion
During development of the HPLC method, variables that
could have influence on the chromatographic performance must
be taken into consideration. Generally, HPLC separation depends
on the physical and chemical properties of the compounds,
composition and pH of the mobile phase, column temperature,
and stationary phase properties. According to this, in the
screening phase all variables that could influence the separation
of MPA and MMF as well as their domains were determined.
During preliminary experiments, the nature of the stationary
phase was firstly investigated. The C18 packing columns were
shown to be the most suitable according to the nature of the
compounds. The paramount of modern pharmaceutical
analysis is to provide higher column efficiency and shorter
analysis time. On one hand, the XTerra C18 column enabled
better peak shape of the compounds than conventional C18
columns, which is because of its hybrid technology. On the
other hand, monolithic packing as a new development can
achieve a high-speed separation. Considering this, the previ-
ously mentioned columns were included in the experimental
design to compare their influence on chromatographic sepa-
ration, and afterwards the comparison of the efficiency and
analysis speed was performed.
Afterwards, the percentage of organic modifier was examined.
Between organic modifiers, acetonitrile showed the best char-
acteristics considering peak shape and retention parameters. As
the retention time of compounds was unreasonably prolonged
when the amount of acetonitrile was below 25%, this per-
centage was chosen as the low level. On the other hand, 35% of
organic modifier was chosen for the high level because above
this percentage, no separation could be achieved.
Considering peak broadening and symmetries, the addition
of phosphate buffer was necessary. Good peak symmetries were
achieved with 15mM KH2PO4, and because the concentration
of phosphate buffer showed no influence on the retention para-
meters, buffer concentration was not taken into consideration
during further investigation. 
The pH values of the water phase were varied from 2.4 to 4.8.
This decision was based on the stability of MMF and good
 separation from its degradation product, MPA.
The temperature was examined in the range from 25 to
35ºC. Because the peak symmetries of both compounds were
considerably worse at higher temperatures, a wider range of
temperature was not investigated.
After preliminary experiments, 24–1 fractional factorial design
was performed. The investigated variables and their domains
are presented in Table I. High and low levels of each variable are
based on the preliminary investigations and are denoted as +1
and –1. The experimental plan for fractional factorial design is
reported in Table II, and it must be noted that all experiments
were performed randomly and in duplicate in order to estimate
the experimental error. The observed response was retention
factor for both substances, and according to obtained values
standardized effects were calculated. Based on experimental
error and absolute values of standardized effects, the signifi-
cance of examined factors was evaluated in the same way as
explained in the “Experimental design and methodology” sec-
tion. Pareto charts, of which the length of the bars is propor-
tional to the absolute value of the standardized effects, are
presented in Figure 2. As has already been said, a line in the
Pareto chart indicated the threshold for a test at level p = 0.05
(for tcrit = 4.303).
The standardized effects are also presented in Figure 2 in
order to see whether the influence of the variable on the
response is positive or negative. If a standardized effect is a neg-
ative value, it means that an increase in a variable leads to a
Table I. Investigated Variables and their Domains 
Investigated levels
Variables Low level (–1) High level (+1)
Column Chromolith XTerra
pH value of the water phase 2.4 4.8
Column temperature (°C) 25 35
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decrease in a retention parameter and if it is positive the
increase of variable leads also to increase of the response. From
the results obtained, the following conclusions could be made.
The percentage of acetonitrile and pH of the water phase
showed statistically important influences on the chromato-
graphic behavior of both substances. Both variables had a neg-
ative effect on the retention factor of MPA, though the
percentage of acetonitrile had a negative and pH of the water
phase a positive effect on the retention parameter of MMF.
These variables have been further investigated and optimized
using RSM.
As could be expected, due to the fact that both columns are
C18, no significant influence of the columns on the retention
behavior of the investigated compounds was noticed. During
experiments, it was observed that the Chromolith column pro-
vided much shorter analysis time and the XTerra column
enabled better peak symmetries. In order to decide which
column to use in further optimization, the columns were com-
pared and results are presented in Table III. All parameters
were obtained with the same composition of the mobile phase
and were further compared. Due to the structure of the Chro-
molith column, analysis could be performed at a flow rate of 5
mL/min. The Chromolith column is made by sol gel tech-
nology, which enables the formation of highly porous material
containing macropores and mesopores in its structure. The
large pores (typically 2 µm) are responsible for a low flow
resistance and therefore allow the application of high eluent
flow rates, while the small pores (approximately 12 nm) ensure
sufficient surface area for separation efficiency. Due to this,
higher flow rates can be used while the resolution of silica
rod column is much less affected in comparison to particulate
materials after increasing the flow rate and maintaining low
column pressure (19). So, the flow rate could be increased
with no significant increase of back-pressure. On the other
hand, the flow rate on the Xterra column was constant and
kept at 1 mL/min. These flow rates allowed much shorter
analysis times of the compounds on the Chromolith column.
But this was not all: the Chromolith column also showed a
higher efficiency, and a slightly smaller amount of acetonitrile
was used for analysis. Based on these results, we decided to use
the Chromolith column in further optimization and validation
of the method.
Another variable that showed no influence on the chromato-
graphic behavior of MPA and MMF was column temperature.
The temperature was held at 25°C in further optimization. This
decision was based on the previously mentioned fact that sym-
metries of the peaks were much better at a lower temperature.
Table II. Plan of Experiments in Fractional Factorial
Design for MMF and MPA
VariablesExp.
no. A B C D
1 –1 –1 –1 –1
2 +1 –1 –1 +1
3 +1 +1 –1 –1
4 +1 –1 +1 –1
5 –1 –1 +1 +1
6 +1 +1 +1 +1
7 –1 +1 –1 +1
8 –1 +1 +1 –1
Figure 2. Pareto charts of standardized effects (absolute values) obtained
from the fractional factorial design for MPA and MMF.
Table III. Performances of Chromolith Column and
XTerra Column
Parameter Monolith column XTerra
Mobile phase 35% ACN–15Mm 35% ACN–15Mm
KH2PO4, pH adjusted KH2PO4, pH adjusted
to 4.0 to 4.0
Flow rate 5 1
(mL/min)
Analysis time 1.27 8.34
(min)
Need of ACN 2.22 2.92
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Because no factor interactions and optimal conditions could
be obtained from fractional factorial design, RSM was further
applied.
Two variables that needed further optimization were per-
centage of acetonitrile in the mobile phase and pH value of the
water phase. As mentioned, RSM was applied and the influ-
ences of the variables on the retention parameters are clearly
shown in Figure 3. The relationship between variables and
response is the best described with the following equations:
z = 53.369 – 3.008x – 0.983y + 0.052x2 – 0.169xy + 1.07y2
for MMF, and
z = 148.977 – 8.207x – 0.712y + 0.109x2 + 0.16xy – 0.659y2
for MPA,
where y is the concentration of acetonitrile, x is the pH value
of the water phase, and z is the retention factor.
Not only separation, but also reasonable retention time of
MPA was the goal of this optimization. Based on the response
surface plots, it can be noticed that interactions exist between
variables x1 and x2 for MMF. The higher the pH values of the
water phase, the bigger the influence of the percentage of ace-
tonitrile. This interaction is not drastically emphasized for
MPA. For both substances, the percentage of acetonitrile has
the biggest influence on retention time. It can be concluded
that optimal retention factors for both compounds were
achieved with 30% of acetonitrile. Below this percentage, the
retention of the compounds are unnecessary long, especially
for MPA, and also for MMF when pH of the water phase is
higher than 4.0. On the other hand, when pH of the water
phase is between 2.4 and 3.6, the retention factor of MPA was
unreasonably high. Because of this compound, it was decided
to work on higher pH values but not higher than 4.3, consid-
ering that above this pH, no baseline separation could be
achieved. One more thing was noticed. Peak symmetries for
both compounds were the best when pH of the water phase was
4.0. Based on all observations, the most suitable mobile phase
was chosen and the mobile phase composition is described in
detail in the “Chromatographic conditions” section.
Validation of the optimized method
After the optimization procedure, validation was carried out
according to ICH guidelines (31). During the validation
process, the method was tested for selectivity, linearity, preci-
sion, limit of detection (LOD), and limit of quantitation (LOQ).
The selectivity of the method was investigated by observing
potential interferences between MMF and its degradation
product with tablet excipient, and no interfering peaks were
noticed, which can be observed in Figure 4.
The internal standard method was used for quantitation.
After the injection of every prepared solution into the HPLC
system, the peak areas were measured and the ratios of the
peak area of the investigated substances to that of the internal
standard were calculated. The linearity of the relationships
between peak areas and concentrations for MMF and MPA were
investigated by analyzing standard solutions. Standard solu-
tions were prepared in the concentration range 0.05–0.5
mg/mL for MMF and 0.5–5 µg/mL for MPA. Six solutions of
MMF and MPA were prepared in the mobile phase, with addi-
tion of internal standard to yield a final concentration of 10
µg/mL, and each were injected in triplicate. Regression lines
for MMF and MPA were constructed by the method of least-
squares. Data from regression analysis are presented in Table
IV and the difference of intercepts from zero (p = 0.05, ttab =
Figure 3.Three-dimensional retention factor diagrams k1 = ƒ (% AcN, pH)
for MMF (A) and MPA (B).
Figure 4. Representative chromatograms of working solution of MMF (A),
MPA (B), and MMF and MPA from dosage form, Cellcept capsules (C) on
Chromolith column. Mobile phase: ACN–15mM KH2PO4 buffer with pH
adjusted to 4.0 with 85% orthophosphoric acid (35:65, v/v); column tem-
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2,571) was found to be insignificant.
The precision of the chromatographic method was investi-
gated for three concentrations from calibration curves of
each investigated analyte. Three solutions for each concen-
tration level of analyzed compounds were freshly prepared
prior to analysis. The results and important statistical data are
given in Table V, and it could be concluded that the method
showed satisfactory precision.
Furthermore, LOD was measured as the lowest amount of
the analyte that may be detected to produce a response which
is significantly different from that of a blank. The values of LOD
were experimentally determined. The LOD was 0.03 µg/mL
for MMF and 0.025 µg/mL for MPA.
LOQ was estimated as the lowest amount of the analyte that
can be reproducibly quantitated above the baseline noise with
a RSD ≤ 3% for replicated injections. Obtained values were 0.10
µg/mL for MMF and 0.09 µg/mL for MPA.
All data met the criteria from the ICH regulations. Fur-
thermore, the applicability of the proposed method for the
assay of dosage form was examined by analyzing commer-
cially available Cellcept capsules. Chro-
matograms of the standard and test
solutions, together with phenacetin as
the internal standard, are shown in
Figure 5. Obtained data from dosage
form are presented in Table VI, and it
could be concluded that the low RSD
value indicates satisfactory repeatability
of the method.
According to these results, it must be
concluded that a precise, sensitive, rapid,
and solvent- and time-saving method was developed on the
Chromolith column.
Conclusion
With the assistance of experimental design, a new method
has been developed and validated for the simultaneous deter-
mination of MMF and its degradation product MPA in dosage
form. It is ideal for routine analysis considering its simplicity
and short analysis time of only 1.27 min per run. Aside from
this method’s outstanding ability to save analysis time and
solvent, during the validation process, the method also showed
outstanding sensitivity, precision, and selectivity.
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Table IV. Regression Analysis Data
Compound y = ax + b r* Sa† Sb† ta‡
MMF 26.910x – 0.340 0.9994 2.100 0.550 2.37
MPA 0.0374x + 0.0015 0.9999 0.0017 0.004 1.58
*r—correlation coefficient.
† Sa, Sb—standard deviations of the slope and intercept.
‡ t—calculated deviation value for intercept.
t0.05 – 2.571
Table V. Precision of the Assay for Three Standard
Solutions of Three Different Concentrations 
Concentration Amount SD RSD
Compound (mg/mL) found (mg/mL) (%)*
MMF 0.1 0.097 0.001 0.77
0.2 0.198 0.001 0.68
0.3 0.300 0.003 1.11
MPA 1 1.004 0.012 1.24
2 1.983 0.018 0.89
3 2.975 0.051 1.70
* RSD—relative standard deviation.
Table VI. Assay of MFM and MPA in Cellcept Capsules
RSD Found in R
Compound Taken Found SD (%) mg/capsule (%)
MMF (mg/mL) 0.2 0.203 0.004 1.92 253.70 101.48
MPA (µg/mL) 2 0.064 0.002 3.54 0.064
MAC*
* MAC—maximum allowed content.
Figure 5. Representative chromatograms of working solution of MMF and
phenacetin as internal standard (A), MPA and phenacetin (B), and MMF and
MPA from dosage form, Cellcept capsules, and phenacetin (C) on Chro-
molith column. Mobile phase: ACN–15mM KH2PO4 buffer with pH
adjusted to 4.0 with 85% orthophosphoric acid (35:65, v/v); column tem-
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